ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.14.

Several research analysts recently commented on ALXO shares. Stifel Nicolaus reduced their price target on ALX Oncology from $3.00 to $1.50 and set a “hold” rating for the company in a research report on Friday. UBS Group reduced their price target on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Piper Sandler raised their price objective on ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $3.00 in a research report on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO opened at $1.06 on Friday. The stock has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.62. ALX Oncology has a 52 week low of $0.95 and a 52 week high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The stock has a market capitalization of $55.91 million, a PE ratio of -0.36 and a beta of 1.01.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently made changes to their positions in the company. Barclays PLC increased its stake in shares of ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after purchasing an additional 42,185 shares during the period. GSA Capital Partners LLP bought a new position in shares of ALX Oncology during the third quarter worth approximately $88,000. Wellington Management Group LLP increased its stake in shares of ALX Oncology by 15.2% during the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after purchasing an additional 22,114 shares during the period. Verition Fund Management LLC increased its stake in shares of ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after purchasing an additional 100,454 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of ALX Oncology by 110.3% during the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after purchasing an additional 121,113 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.